X

Trial Profile

Phase 1b multicenter, placebo-controlled Study of Gemini (Glycopyranosyl lipid adjuvant) in CKD Patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyranosyl lipid adjuvant (Primary)
Indications Renal failure
Focus Adverse reactions
Acronyms GEMINI-CKD program

Most Recent Events

03 Dec 2024 New trial record
02 Dec 2024 According to a Revelation Biosciences media release, USFDA has accepted its IND application for Gemini, which allows the Company to initiate its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease (CKD), planned to begin in early 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com